Inovio Pharmaceuticals Inc (INO) Earns Buy Rating from Stifel Nicolaus
Inovio Pharmaceuticals Inc (NASDAQ:INO)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a research report issued on Thursday. They currently have a $11.00 target price on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 39.59% from the stock’s current price.
A number of other analysts have also issued reports on the company. Maxim Group lifted their price target on Inovio Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday. Aegis reaffirmed a “buy” rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 17th. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 15th. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 11th. Finally, Nomura reaffirmed a “buy” rating and issued a $40.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $19.16.
Inovio Pharmaceuticals (NASDAQ:INO) traded down 1.38% during mid-day trading on Thursday, reaching $7.88. The company had a trading volume of 1,631,705 shares. The stock’s market capitalization is $588.06 million. The stock has a 50 day moving average of $6.68 and a 200 day moving average of $6.81. Inovio Pharmaceuticals has a 52 week low of $5.83 and a 52 week high of $11.62.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The firm had revenue of $10.40 million for the quarter, compared to analyst estimates of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 39.93% and a negative net margin of 199.99%. The business’s revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.11) earnings per share. Analysts anticipate that Inovio Pharmaceuticals will post ($1.10) earnings per share for the current year.
In related news, Director Morton Collins acquired 21,300 shares of the stock in a transaction on Monday, March 27th. The shares were bought at an average price of $6.25 per share, with a total value of $133,125.00. Following the completion of the purchase, the director now owns 142,291 shares of the company’s stock, valued at approximately $889,318.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now directly owns 740,956 shares in the company, valued at approximately $5,927,648. The disclosure for this sale can be found here. Insiders own 9.90% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the period. Russell Investments Group Ltd. acquired a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $559,000. Credit Suisse AG increased its stake in Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 69,068 shares in the last quarter. Geode Capital Management LLC increased its stake in Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after buying an additional 62,045 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Inovio Pharmaceuticals by 32.6% in the third quarter. New York State Common Retirement Fund now owns 230,458 shares of the biopharmaceutical company’s stock worth $2,148,000 after buying an additional 56,631 shares in the last quarter. 28.72% of the stock is currently owned by institutional investors.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.